Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,885,600 | 3,432,400 | 2,072,200 | 1,437,900 | 2,193,700 |
| Marketable Securities | 2,809,100 | 2,355,200 | 1,838,600 | 2,065,900 | 1,393,300 |
| Receivables | 6,036,500 | 5,452,000 | 6,998,600 | 4,173,000 | 4,114,700 |
| Inventories | 1,951,300 | 2,053,800 | 1,983,900 | 2,164,700 | 1,916,600 |
| TOTAL | $14,014,900 | $13,775,400 | $13,337,600 | $10,055,100 | $9,779,100 |
| Non-Current Assets | |||||
| PPE Net | 3,482,200 | 3,395,700 | 3,358,500 | 3,262,600 | 3,221,600 |
| Investments And Advances | 6,838,000 | 5,631,300 | 3,900,300 | 3,543,700 | 3,135,600 |
| Intangibles | 6,700 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1,093,000 | 869,101 | 889,500 | 910,800 | 1,027,000 |
| TOTAL | $11,419,900 | $9,896,101 | $8,148,300 | $7,717,100 | $7,384,200 |
| Total Assets | $25,434,800 | $23,671,500 | $21,485,900 | $17,772,200 | $17,163,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 564,000 | 427,000 | 476,000 | 542,900 | 475,500 |
| Other current liabilities | 2,206,800 | 2,061,000 | 2,018,000 | 1,492,200 | 1,644,200 |
| TOTAL | $3,932,500 | $3,714,800 | $3,732,400 | $3,217,800 | $2,697,400 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,980,000 | 1,979,600 | 1,979,200 | 1,978,900 | 1,978,500 |
| Deferred Revenues | 442,000 | 507,800 | 520,000 | 464,900 | 577,700 |
| Other Non-Current Liabilities | 680,200 | 662,600 | 596,300 | 571,500 | 687,100 |
| TOTAL | $2,733,500 | $2,698,700 | $2,626,200 | $2,577,400 | $3,440,600 |
| Total Liabilities | $6,666,000 | $6,413,500 | $6,358,600 | $5,795,200 | $6,138,000 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 108,539 | 107,543 | 106,955 | 106,544 | 107,132 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 18,968,300 | 16,739,300 | 15,107,100 | 12,008,200 | 10,893,000 |
| Other shareholders' equity | -26,100 | 9,300 | 15,300 | 15,900 | 29,000 |
| TOTAL | $18,768,800 | $17,258,000 | $15,127,300 | $11,977,000 | $11,025,300 |
| Total Liabilities And Equity | $25,434,800 | $23,671,500 | $21,485,900 | $17,772,200 | $17,163,300 |